drugset / Trial / NCT02103686

Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

NCT02103686

Phase 1 Completed 30 enrolled IlDong Pharmaceutical Co Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to: 1. Compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to immediate release capsule(150mg \* 2). 2. Evaluate the effectiveness of food to pharmacokinetics profile of Pregabalin sustained release tablet.

Timeline

Start
2012-11
Primary completion
2012-12
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg

Indications

No indication recorded.